Fall Skin Care Sale

Cholesterol Management

References

1. Nelson D, Cox M. Principles of biochemistry. 4th ed. W.H. Freeman & Co.; 2005.

2. Haines TH (July 2001). "Do sterols reduce proton and sodium leaks through lipid bilayers?". Prog. Lipid Res. 40 (4): 299–324.

3. Antonopoulos S. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3145-3408.

4. Antonopoulos S. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3145-3408.

5. Tribble DL et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size.Atherosclerosis. 1992 Apr;93(3):189-99.

6. Chait A et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993 Apr;94(4):350-6.

7. Liu ML et al. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1492-7.

8. Koba S et al. Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis. J Atheroscler Thromb. 2008 Oct;15(5):250-60.

9. Antonopoulos S. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3145-3408.

10. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2002 Sep 6;296(5):1051-7.

11. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2002 Sep 6;296(5):1051-7.

12. Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am J Physiol Endocrinol Metab. 2003 Jun;284(6):E1112-8.

13. Turhan S, Tulunay C, Gulec S, et al. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis. 2007 May;18(3):159-62.

14. Steinberg D. Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy: part I. The Journal of Lipid Research 2004 Apr.;45(9):1583-1593.

15. Reaven P, Witztim J. Oxidized Low Density Lipoproteins in Atherogenesis: Role of Dietary Modification. Annual Reviews in Nutrition 1996 Feb.;16:51-70.

16. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. The Journal of Lipid Research 2008 Dec.;50(Supplement):S376-S381.

17. Chouinard JA et al. Oxidized-LDL induce morphological changes and increase stiffness of endothelial cells. Exp Cell Res. 2008 Oct 1;314(16):3007-16.

18. Havranek EP. Primary prevention of CHD: nine ways to reduce risk. Am Fam Physician 1999 Mar.;59(6):1455-63, 1466.

19. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther 2010;4:383-413.

20. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010 Jan.;375(9709):132-140.

21. Schnohr P. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12000 men and women from The Copenhagen City Heart Study. European Heart Journal 2002 Apr.;23(8):620-626.

22. Ridker PM, Danielson E, Fonseca FA,, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.

23. Daviglus ML, Stamler J, Pirzada A, et al.. Favorable cardiovascular risk profile in young women and long-term risk of cardiovas-cular and all-cause mortality. JAMA. 2004;292(13):1588-1592

24. Sobal G et al. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. Prostaglandins Leukot Essent Fatty Acids. 2000 Oct;63(4):177-86.

25. Nivoit P et al. Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients. Diabetologia. 2003 Nov;46(11):1550-8.

26. Toma L et al. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochem Biophys Res Commun. 2009 Dec 18;390(3):877-82.

27. Dong Y et al. Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase. J Cell Mol Med. 2009 Sep;13(9A):2899-910.

28. Calvo C. [Non-enzymatic glycosylation of lipoproteins in the pathogenesis of atherosclerosis in diabetics]. Rev Med Chil. 1997 Apr;125(4):460-5.

29. Calvo C. [Non-enzymatic glycosylation of lipoproteins in the pathogenesis of atherosclerosis in diabetics]. Rev Med Chil. 1997 Apr;125(4):460-5.

30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein in plasma without use of preparative ultracentrifuge. Clin Chem 1972;18:499–502.

31. http://www.bhlinc.com/index.php

32. http://www.liposcience.com/

33. Barter PJ. Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism? Circulation 2006 Mar.;113(12):1553-1555.

34. Devaraj S, Siegel D, Jialal I. Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP? Curr Atheroscler Rep 2011 Feb.;13(1):31-42.

35. Fung EC, Crook MA. Statin Myopathy: A Lipid Clinic Experience on the Tolerability of Statin Rechallenge. Cardiovasc Ther 2011 Apr.;:no-no.

36. Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010 Oct.;42(4):469-479.

37. Kastelein J, Akdim F, Stroes E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New England Journal of Medicine 2008;

38. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness. N Engl J Med 2009 Nov.;361(22):2113-2122.

39. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis). J Am Coll Cardiol 2010 Jun.;55(24):2721-2726.

40. West AM, Anderson JD, Meyer CH, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 2011 Apr.;

41. Davidson MH. Therapies targeting exogenous cholesterol uptake: new insights and controversies. Curr Atheroscler Rep 2011 Feb.;13(1):95-100.

42. Antonopoulos S. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3145-3408.

43. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. New England Journal of Medicine 1997; 336:1117-1124

44. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. New England Journal of Medicine 1997; 336:1117-1124

45. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999 Feb 8;159(3):285-93

46. Lane M, Black A and Ingram D. Calorie restriction in nonhuman primates: implications for age-related disease risk. Journal of Anti-Aging 1998;

47. Walford RL, Mock D, Verdery R and MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J Gerontol A Biol Sci Med Sci. 2002;57(6):B211-224

48. Fontana L, Meyer TE, Klein S and Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA. 2004;101(17):6659-6663

49. Fontana L, Klein S, Holloszy JO and Premachandra BN. Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. J Clin Endocrinol Metab. 2006;91(8):3232-3235

50. Meyer TE, Kovács SJ, Ehsani AA, Klein S, Holloszy JO and Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol. 2006;47(2):398-402

51. About CALERIE. http://calerie.dcri.duke.edu/about/index.html

52. Lefevre M, Redman LM, Heilbronn LK, et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. 2009;203(1):206-213

53. Dzugan SA and Smith AR. Hypercholesterolemia treatment: a new hypothesis or just an accident? Med Hypotheses. 2002 Dec;59(6):751-6.

54. Windler E et al. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease. Maturitas. 2007 Jul 20;57(3):239-46.

55. Tan RS Salazar JA. Risks of testosterone replacement therapy in ageing men. Expert Opin Drug Saf. 2004 Nov;3(6):599-606.

56. McCarty MF. Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Medical Hypotheses 2001;56(3):314-317.

57. Bertolini S, Donati C, Elicio N, Daga A, Cuzzolaro S, Marcenaro A, Saturnino M, Balestreri R. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int J Clin Pharmacol Ther Toxicol 1986 Nov;24(11):630-7

58. Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis 1984 Jan;50(1):73-83

59. Donati C, Bertieri RS, Barbi G. Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients Clin Ter 1989 Mar 31;128(6):411-22

60. Tonutti L, Taboga C, Noacco C. Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia. Minerva Med 1991 Oct;82(10):657-63

61. Cunningham E. Is Red Yeast Rice Safe and Effective for Lowering Serum Cholesterol? J Am Diet Assoc 2011 Feb.;111(2):324.

62. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice(Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006;1(1):4.

63. Lu Z, Kou W, Du B, Wu Y, Zhao S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. The American journal of … 2008;

64. Becker D, Gordon R, Halbert S. Red yeast rice for dyslipidemia in statin-intolerant patients. Annals of internal … 2009;

65. Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010 Jan.;105(2):198-204.

66. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 2010 Oct.;170(19):1722-1727.

67. Reinhart KM, Talati R, White CM, Coleman CI. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev 2009 Jun.;22(1):39-48.

68. Khoo YSK, Aziz Z. Garlic supplementation and serum cholesterol: a meta-analysis. J Clin Pharm Ther 2009 Apr.;34(2):133-145.

69. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med 2000 Sep.;133(6):420-429.

70. Reinhart KM, Talati R, White CM, Coleman CI. The impact of garlic on lipid parameters: a systematic review and meta-analysis. Nutr Res Rev 2009 Jun.;22(1):39-48.

71. Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2008;8:13.

72. Nampoothiri SV et al. In vitro antioxidant and inhibitory potential of Terminalia bellerica and Emblica officinalis fruits against LDL oxidation and key enzymes linked to type 2 diabetes. Food Chem Toxicol. 2011 Jan;49(1):125-31.

73. Kim HJ et al. Influence of amla (Emblica officinalis Gaertn.) on hypercholesterolemia and lipid peroxidation in cholesterol-fed rats. J Nutr Sci Vitaminol (Tokyo). 2005 Dec;51(6):413-8.

74. Yokozawa T et al. Amla (Emblica officinalis Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. Br J Nutr. 2007 Jun;97(6):1187-95.

75. Akhtar MS et al. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr. 2011 Apr 18.

76. Chen TS et al. Supplementation of Emblica officinalis (Amla) extract reduces oxidative stress in uremic patients. Am J Chin Med. 2009;37(1):19-25.

77. Akhtar MS et al. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr. 2011 Apr 18.

78. Kim HY et al. The protective role of amla (Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr. 2010 Feb;103(4):502-12.

79. Rao TP et al. Amla (Emblica officinalis Gaertn.) extracts reduce oxidative stress in streptozotocin-induced diabetic rats. J Med Food. 2005 Fall;8(3):362-8.

80. Doi K, Nakamura T, Aoyama N, Matsurura M, Kawara A, Baba S. Metabolic and nutritional effects of long-term use of glucomannan in the treatment of obesity. In: Oomura Y, ed. Progress in Obesity Research. John Libbey & Company, Ltd., 1990:507-14.

81. Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovasc Ther 2010 Aug.;28(4):202-215.

82. Anderson J, Randles K. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. Journal of the American College of Nutrition 2004; 23(1):5-17

83. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999 Jan.;69(1):30-42.

84. AbuMweis SS, Jew S, Ames NP. ß-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 2010 Dec.;64(12):1472-1480.

85. Baker WL, Tercius A, Anglade M, White CM, Coleman CI. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann Nutr Metab 2009;55(4):368-374.

86. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999 Jan.;69(1):30-42.

87. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999 Jan.;69(1):30-42.

88. Brighenti F, Casiraghi M, Canzi E. Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers. European journal of Clinical Nutrition 1999;53:726-733

89. Li S, Guerin-Deremaux L, Pochat M, et al. NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study. Appl Physiol Nutr Metab 2010 Dec.;35(6):773-782.

90. Salo P, Wester I. Low-Fat Formulations of Plant Stanols and Sterols. Am J Cardiol 2005 Jul.;96(1):51-54.

91. Weingartner O, Bohm M, Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. European Heart Journal 2008 Sep.;30(4):404-409.

92. Calpe-Berdiel L. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis 2009;

93. Shrestha S, Freake HC, McGrane MM, Volek JS, Fernandez ML. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr 2007 May;137(5):1165-1170.

94. Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovasc Ther 2010 Aug.;28(4):202-215.

95. Normén L, Holmes D, Frohlich J. Plant sterols and their role in combined use with statins for lipid lowering. Curr Opin Investig Drugs. 2005;6:307–16.

96. Electronic Code of Federal Regulations (http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&rgn=div8&view=text&node=21:2.0.1.1.2.5.1.14&idno=21)

97. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-2497.

98. Lichtenstein AH. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 Oct.;26(10):2186-2191.

99. Ulbricht C, Basch E, Szapary P, et al. Natural Standard Research Collaboration. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 2005 Dec.;13(4):279-290.

100. Ulbricht C, Basch E, Szapary P, et al. Natural Standard Research Collaboration. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med 2005 Dec.;13(4):279-290.

101. Singh R, Niaz M. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovascular drugs and therapy 1994;

102. Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003 Aug.;290(6):765-772.

103. Nohr LA, Rasmussen LB, Straand J. Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study. Complement Ther Med 2009 Jan.;17(1):16-22.

104. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 1995 Aug.;333(5):276-282.

105. Bruckert E, Rosenbaum D. Lowering LDL-cholesterol through diet: potential role in the statin era. Curr. Opin. Lipidol. 2011 Feb.;22(1):43-48.

106. Reynolds K, Chin A, Lees KA, Nguyen A, Bujnowski D, He J. A meta-analysis of the effect of soy protein supplementation on serum lipids. Am J Cardiol 2006 Sep.;98(5):633-640.

107. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 1995 Aug.;333(5):276-282.

108. Taku K, Umegaki K, Sato Y, et al. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2007 Apr.;85(4):1148-1156.

109. Sangle GV et al. Impairment of mitochondrial respiratory chain activity in aortic endothelial cells induced by glycated low-density lipoprotein. Free Radic Biol Med. 2010 Mar 15;48(6):781-90.

110. Roy Chowdhury SK et al. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E89-98.

111. Cenedella RJ et al. Concentration and distribution of ubiquinone (coenzyme Q), the endogenous lipid antioxidant, in the rat lens: effect of treatment with simvastatin. Mol Vis. 2005 Aug 10;11:594-602.

112. Littarru GP and Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007 Jun;7 Suppl:S168-74.

113. Reaven P, Witztim J. Oxidized Low Density Lipoproteins in Atherogenesis: Role of Dietary Modification. Annual Reviews in Nutrition 1996 Feb.;16:51-70.

114. Karppi J, Nurmi T, Kurl S, Rissanen TH, Nyyssönen K. Lycopene, lutein and beta-carotene as determinants of LDL conjugated dienes in serum. Atherosclerosis 2010 Apr.;209(2):565-572.

115. Ried K, Fakler P. Protective effect of lycopene on serum cholesterol and blood pressure: Meta-analyses of intervention trials. Maturitas 2011 Apr.;68(4):299-310.

116. Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochem Biophys Res Commun 1997 Apr.;233(3):658-662.

117. Yoshida H, Yanai H, Ito K, et al. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis 2010 Apr.;209(2):520-523.

118. Badiou S et al. Vitamin E supplementation increases LDL resistance to ex vivo oxidation in hemodialysis patients. Int J Vitam Nutr Res. 2003 Jul;73(4):290-6.

119. Tesoriere L et al. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients. Free Radic Res. 2001 May;34(5):529-40.

120. Li D, Saldeen T, Romeo F, Mehta JL. Relative effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation and superoxide dismutase and nitric oxide synthase activity and protein expression in rats. J Cardiovasc Pharmacol Ther. 1999 Oct;4(4):219-26.

121. McCarty MF. Gamma-tocopherol may promote effective no synthase function by protecting tetrahydrobiopterin from peroxynitrite. Med Hypotheses. 2007;69(6):1367-70.

122. Saito F, Iwamoto S, Yamauchi R. Reaction products of gamma-tocopherol with (E)-4-oxo-2-nonenal in acidic acetonitrile. Biosci Biotechnol Biochem. 2010;74(1):168-74.

123. Singh I, Turner AH, Sinclair AJ, Li D, Hawley JA. Effects of gamma-tocopherol supplementation on thrombotic risk factors. Asia Pac J Clin Nutr. 2007;16(3):422-8.

124. Aviram M, Dornfeld L, Kaplan M, et al. Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs Exp Clin Res 2002;28(2-3):49-62.

125. Sezer ED, Akçay YD, Ilanbey B, Yildirim HK, Sözmen EY. Pomegranate wine has greater protection capacity than red wine on low-density lipoprotein oxidation. J Med Food 2007 Jun.;10(2):371-374.

126. Esmaillzadeh A et al. Cholesterol-lowering effect of concentrated pomegranate juice consumption in type II diabetic patients with hyperlipidemia. Int J Vitam Nutr Res. 2006 May;76(3):147-51.

127. Fuhrman V et al. Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages. J Nutr Biochem. 2005 Sep;16(9):570-6.

128. Aviram M et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004 Jun;23(3):423-33.

129. Badimon L, Vilahur G, Padro T. Nutraceuticals and atherosclerosis: human trials. Cardiovasc Ther 2010 Aug.;28(4):202-215.

130. Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition 2008 Jul.;88(1):38-50.

131. Jujita H, Yamagami T. Antihypercholesterolemic effect of Chinese black tea extract in human subjects with borderline hypercholesterolemia. Nutr Res 2008, 28:450–456.

132. Roza J, Xian-Liu Z. Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects. Health Med 2007;

133. Urpí-Sardà M, Jáuregui O, Lamuela-Raventós RM, et al. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal. Chem. 2005 May;77(10):3149-3155.

134. Nigdikar S, Williams N, Griffin B. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. The American journal … 1998;

135. Ramirez Boscá A, Soler A, Gutierrez MC. Antioxidant curcuma extracts decrease the blood lipid peroxide levels of human subjects. Age; Volume 18, Number 4, 167-169.

136. Ramirez Boscá A, Carrión-Gutiérrez MA, et al. Effects of the antioxidant turmeric on lipoprotein peroxides: Implications for the prevention of atherosclerosis. Age1997 Jul.;20(3):165-168.

137. Ramirez Boscá A, Soler A, Carrión-Gutiérrez MA, et al. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech Ageing Dev 2000 Apr.;114(3):207-210.

138. Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol. 2009 Apr.;133(2):145-151.

139. Dou X, Fan C, Wo L, et al. Curcumin up-regulates LDL receptor expression via the sterol regulatory element pathway in HepG2 cells. Planta Med 2008 Sep.;74(11):1374-1379.

140. Peschel D, Koerting R, Nass N. Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem 2007 Feb.;18(2):113-119.

141. Soni KB, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J. Physiol. Pharmacol. 1992 Oct.;36(4):273-275.

142. Alwi I, Santoso T, Suyono S, et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 2008 Oct.;40(4):201-210.

143. Baum L, Cheung SKK, Mok VCT, et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol. Res. 2007 Dec.;56(6):509-514.

144. Brown JE, Rice-Evans CA. Luteolin-rich artichoke extract protects low density lipoprotein from oxidation in vitro. Free Radic Res 1998 Sep.;29(3):247-255.

145. Wider B, Pittler MH, Thompson-Coon J, Ernst E. Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst Rev 2009;(4):CD003335.

146. Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung 2000 Mar.;50(3):260-265.

147. Bundy R, Walker AF, Middleton RW, Wallis C, Simpson HCR. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine 2008 Sep.;15(9):668-675.

148. Lupattelli G, Marchesi S, Lombardini R, et al. Artichoke juice improves endothelial function in hyperlipemia. Life Sci 2004 Dec.;76(7):775-782.

149. Morgan JM, Capuzzi DM, Baksh RI, et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003 Jun.;91(12):1432-1436.

150. Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol 2000 Mar.;35(3):640-646.

151. Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol 2010 Nov.;8(6):820-830.

152. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009 Jan.;202(1):68-75.

153. Duggal JK, Singh M, Attri N, et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J. Cardiovasc. Pharmacol. Ther. 2010 Jun.;15(2):158-166.

154. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009 Jul.;32(7):365-372.

155. Eslick GD, Howe PRC, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int. J. Cardiol. 2009 Jul.;136(1):4-16.

156. Shafiq N, Singh M, Kaur S, Khosla P, Malhotra S. Dietary treatment for familial hypercholesterolaemia. Cochrane Database Syst Rev 2010;(1):CD001918.

157. McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? Curr Atheroscler Rep 2009 Nov.;11(6):470-476.